Barely two weeks after the British press went bananas over cancer research published in the Proceedings of the National Academy of Sciences, the US press took a turn. This time, though, the breathtaking results were published in that prestigious medical journal, the New York Times.
It's odd that the media went berserk over this article. The substance was not new -many reporters had written articles about the subject over the years. Dr Judah Folkman at Harvard Medical School has been working on two natural factors that cut off blood supply to tumors, angiostatin and endostatin. He reported in November in Nature that these anti-angiogenesis factors work surprisingly well in shrinking tumors implanted on mice. The Times' suburban rival, Newsday, published an article in November. And back in January, the Times itself ran a long, thoughtful profile of Folkman and his work.
The 'news' that created a tidalwave of follow-up stories was this: the New York Times article on Sunday, May 3rd had hot quotes and great play. Gina Kolata quoted James Watson saying, "Judah is going to cure cancer in two years." The Times report also declared that the National Cancer Institute (NCI) had made the drugs their top priority. And to top it off, the story ran on page one, above the fold, giving the Times' own influential imprimatur to the report. Of course, the Times dutifully reported that the breathtaking results were only in mice -human trials haven't even started -and many caveats were responsibly placed high up in the story. But the words that resonated were simply these: cancer and cure.
The first wave of stories mostly tried to match the Times. The banner headline in USA Today the next day was "Cancer War May Have New Weapon." The story made it seem simple: "Mounting evidence suggests that doctors may be able to wipe out cancer by cutting off the tumor's blood supply." Sounds like a cure, even though Folkman himself was quoted saying, "Will this work in humans? No one knows." The story played all day Monday on CNN and led national TV newscasts that night.
Other reporters who tried to resist the story for its obvious hype were sucked into the vortex that the Times story itself created. First to go were the business reporters, after EntreMed, the company licensed to produce angiostatin and endostatin, saw its stock value quadruple in a matter of hours, on the basis of the Times story. Next, the more cautious science reporters were dragooned into doing the story after editors decided that it simply couldn't be ignored.
EntreMed's stock value quadrupled on the basis of the Times story
Here's how Rick Weiss at the Washington Post put it: "Two experimental cancer drugs whose ability to shrink tumors in mice triggered a stampede of interest earlier this week are unlikely to have a huge effect on human cancer if experience with similar drugs is an indication, several experts said yesterday." Many reports mentioned the checkered histories of interferon and interleukin. The Boston Globe's sober story ran a headline "Caution is Urged Over New Drugs." The report noted that Folkman canceled a planned lecture after the story broke because he didn't want to be accosted by photographers and TV cameras.
The Times itself published a more cautionary story as momentum swelled over the original report, as well as a letter from James Watson denying the two-years-to-a-cure quote -though Watson said he had spoken to Kolata at a dinner party and he reiterated that he's very enthusiastic about the drugs. Next came a correction in the Times. Dr Klausner at the NCI did not say that the drugs are the institute's top priority, though, splitting a semantic hair, Klausner did say that nothing at the institute has a higher priority.
Soon the news was not about the science at all -but about the Times' story. Newsday, for example, noted "some science journalists are now complaining that the story was old news, overplayed, and that the subsequent frenzy of stories cruelly gave false hope to those with the disease." The article quoted Shannon Brownlee at US News & World Report saying "I would never say to my editors, 'Let's put this one on the cover'." But that's where the story of the story ended up. The spectacle became the subject of cover stories not just for US News, but for Time and Newsweek as well. Headlines managed to work in references to both hope and hype.
And as if there weren't enough angles already, the Los Angeles Times reported, "several publishing houses confirmed Tuesday that they had received copies of a book proposal about the alleged cancer cure from… an agent representing Gina Kolata." This revelation sparked a new spate of articles, including one in the Baltimore Sun, asking whether it's ethical for a reporter in Kolata's position to cash in on the intense public interest she created. The New York Times ran an article on this subject, as well, noting that Kolata had withdrawn her proposal.
But across the East River, a colleague of hers is no doubt smiling broadly. Bob Cooke at Newsday had been circulating a book proposal on Folkman's work, and after the Kolata story broke, it didn't take long for a publisher to bite. The reported advance: one million dollars.
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